# A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels

> **NCT00271557** · PHASE3 · COMPLETED · sponsor: **Scios, Inc.** · enrollment: 305 (actual)

## Conditions studied

- Heart Failure, Congestive
- Heart Decompensation

## Interventions

- **DRUG:** nesiritide

## Key facts

- **NCT ID:** NCT00271557
- **Lead sponsor:** Scios, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-01
- **Primary completion:** —
- **Final completion:** 1997-12
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2011-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271557, "A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00271557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*